GO
Loading...

Enter multiple symbols separated by commas

Actavis Inc

More

  • Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • *Oil prices, commodities lower following China equity selloff. *Teva, Allergan jump after $40.5 bln deal. U.S.-listed shares of Chinese companies slid, including Alibaba and Baozun.

  • NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Teva Pharmaceuticals Industries Ltd., up $10.15 to $72. Restaurant Brands International Inc., up $1.41 to $41.50.

  • The Dutch drugmaker Mylan, which had resisted Teva's advances for three months, is pressing ahead with its offer for Irish drug and ingredients maker Perrigo. Perrigo has turned down Mylan's offer. If they can't work it out, Perrigo might find other suitors as the competitive generic drug industry keeps consolidating.

  • *Oil prices, commodities lower following China equity crash. *Teva, Allergan jump after $40.5 bln deal. The NYSE showed 459 stocks at 52- week lows, the most in a day since Oct. 15.

  • *Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. China's top securities regulator, China Securities Regulatory Commission, said on Monday that Beijing would continue to buy shares to...

  • NEW YORK, July 27- Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, "transformational" merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the...

  • *Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. Chinese ADRs including Alibaba, Baozun, Sohu.com and JD.com slid.

  • China stocks volatile after big fall, Hong Kong rises Monday, 27 Jul 2015 | 10:11 AM ET

    NEW YORK— The worst drop in China's stock market in eight years helped drag down other markets around the world Monday. Faced with a drop in stock prices in Asia, Europe and the U.S., investors moved into traditional safe havens. "There remain very few buyers out there and there are some growing concerns that we're looking at a slowdown in global economic growth," said...

  • *Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. Chinese ADRs including Alibaba, Baozun, Sohu.com and JD.com slid.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • July 27- U.S. stock index futures fell sharply on Monday on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. *Chinese ADRs were set for a rough start with Alibaba, Baozun and Sohu.com off between 2 percent and 5 percent. *Second-quarter S&P 500 earnings have been mixed, with 74 percent of companies beating...

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and...

  • JERUSALEM— Israel's Teva Pharmaceutical Industries Ltd. said Monday it is purchasing Dublin- based Allergan PLC's generic pharmaceuticals business for $40.5 billion, in what Israeli analysts called the largest-ever acquisition by an Israeli company. Statements from both companies say the deal will see Allergan receive $33.75 billion in cash and shares...

  • JERUSALEM— Israel's Teva Pharmaceutical to buy Allergan's generic pharmaceuticals business for $40.5 B.

  • Allergan to acquire Naurex as Teva talks continue Sunday, 26 Jul 2015 | 3:18 PM ET

    Allergan PLC, the Dublin- based pharmaceutical giant, announced Sunday it has agreed to buy Naurex, a developer of drugs for depression and other central nervous system disorders, for $560 million. The announcement comes among reports that Allergan is in talks to sell its enormous generic drug division to Israel- based Teva Pharmaceutical Industries Ltd. The...

  • TEL AVIV, July 26- After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's generic drug business instead could be a smoother ride that will bring bigger returns, faster. Israel- based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-...

  • July 25- Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc's generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. Jerusalem- based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin- based Allergan's...

  • July 25- Israeli drug maker Teva Pharmaceutical Industries Ltd is in talks to combine with Allergan Plc's big generic-drug business, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, one of the people said, according to the...